Mutagenesis vol. 13 no. 6 pp. 601-605, 1998
© 1998 UK Environmental Mutagen Society/Oxford University Press
research-article |
Genetic analysis of PHIP intestinal mutations in MutaTMMouse
Section on Clinical Pharmacology, Division of Medicine, Imperial College School of Medicine, Hammersmith Hospital Ducane Road, London W12 ONN, UK
The mutagenicity of 2-amino-l-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) was investigated in male MutaTMMouse mice administered 20 mg/kg per os for 4 days and killed 7 days later. Genomic DNA was extracted from liver, kidney and small and large intestine and the mutation frequency (MF) at the lacZ locus was determined using a positive selection assay. Mutant lacZ clones from the intestine were characterized further by direct PCR amplification and DNA sequencing. A total of 57 lacZ mutants from PhIP-treated (40) and untreated (18) mice were analysed. In mutants from the PhIP group, 33% were G:C
T:A ransversions from a total of 65% base substitutions (cf. 17% in the vehicle control group). In untreated control mice, 39% of mutants were G:CA:T transitions from a total of 72% base substitutions (cf. 25% in the PhIP group). Interestingly, 20% of the PhIP group mutations were due to G:C base pair (-G) deletions (cf. none in controls). This study confirms that PhIP is mutagenic to the intestine of the MutaTMMouse and induces a spectrum of mutations which are clearly distinct from those spontaneously generated. Also, the PhIP mutation signature in vivo is very similar to that observed for the HPRT and DHFR loci in hamster and human cells in vitro. This suggests that the mutational characteristics of PhIP are well conserved over different reporter genes and between species and that the mutation signature could be of value in molecular epidemiology studies.
1To whom correspondence should be addressed. Tel: +44 181 383 2043; Fax: +44 383 2066; Email: a.lynch{at}rmps.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Creton, H. Zhu, and N. J. Gooderham A Mechanistic Basis for the Role of Cycle Arrest in the Genetic Toxicology of the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) Toxicol. Sci., April 1, 2005; 84(2): 335 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Andreassen, R. Vikse, I.-L. Steffensen, J. E. Paulsen, and J. Alexander Intestinal tumours induced by the food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in multiple intestinal neoplasia mice have truncation mutations as well as loss of the wild-type Apc+ allele Mutagenesis, July 1, 2001; 16(4): 309 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.C. Klein, R.B. Beems, P.E. Zwart, M. Hamzink, G. Zomer, H.v. Steeg, and C.F.v. Kreijl Intestinal toxicity and carcinogenic potential of the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in DNA repair deficient XPA-/- mice Carcinogenesis, April 1, 2001; 22(4): 619 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Masumura, K. Matsui, M. Yamada, M. Horiguchi, K. Ishida, M. Watanabe, K. Wakabayashi, and T. Nohmi Characterization of mutations induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the colon of gpt delta transgenic mouse: novel G:C deletions beside runs of identical bases Carcinogenesis, November 1, 2000; 21(11): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Kulp, M. G. Knize, M. A. Malfatti, C. P. Salmon, and J. S. Felton Identification of urine metabolites of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine following consumption of a single cooked chicken meal in humans Carcinogenesis, November 1, 2000; 21(11): 2065 - 2072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Okochi, N. Watanabe, Y. Shimada, S. Takahashi, K. Wakazono, T. Shirai, T. Sugimura, M. Nagao, and T. Ushijima Preferential induction of guanine deletion at 5'-GGGA-3' in rat mammary glands by 2-amino- 1-methyl-6-phenylimidazo[4,5-b]pyridine Carcinogenesis, October 1, 1999; 20(10): 1933 - 1938. [Abstract] [Full Text] [PDF]
|
|